A toolkit for pharmacists.
Emerging data show that medication errors and adverse events cause significant harm to patients’ health and
well-being. It is estimated that the burden of adverse events due to medicines is now comparable to that of
widespread diseases, such as malaria or tuberculosis....1 The impacts of medication errors also represent a
burden for health systems, with the annual cost associated with medication errors estimated at USD 42 billion
worldwideharm
more
Maintaining proper storage conditions for health commodities is vital to ensuring their quality. Product expiration dates are based on ideal storage conditions and protecting product quality until their expiration date is important for serving customers and conserving resources. Guidelines for the S...torage of Essential Medicines and Other Health Commodities is a practical reference for those managing or involved in setting up a storeroom or warehouse. The guide contains written directions and clear illustrations on receiving and arranging commodities; special storage conditions; tracking commodities; maintaining the quality of the products; constructing and designing a medical store; waste management; and resources. It was written to meet the needs of district-level facilities; however, the guidelines and information it contains apply to any storage facility, of any size, in any type of environment.
more
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s...tandardised questionnaires and the Global TB Drug Facility website.
more
The Priority medicines for mothers and children 2011 list was updated following the 18th Expert Committee Meeting
on Selection and Use of Medicines, the release of new treatment guidelines and feedback from partners following
the 2011 version. In alignment with the UN Global strategy f...or women’s and children’s health; and the recently
launched UN Commission on life‐saving commodities for women and children, the title of this updated list is
renamed as Priority Life‐Saving Medicines for Women and Children.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
The list of emergency medicine has been developed though various consultative meeting and workshops with concerned health professionals and institutions. The medicines in the list should be administered to emergency patients only treated in the health institutions, purchased from legal medicine reta...il outlets on the basis of prescription paper and legal receipt. The stock that should be handled and hoarding of such medicine is prohibited. In addition each medicine administered to emergency patient should be registered in emergency medicine administration registration book.
more
Antimicrobial resistance (AMR) is an increasing worldwide public health problem with
important implications for the European Union (EU). When antibiotics become
ineffective, bacterial infections lead to increased morbidity, use of healthcare,
mortality and cost. Globally, estimates suggest that ...AMR leads to 700 000 deaths
per annum. For the EU, the European Centre for Disease Prevention and Control
(ECDC) has estimated that AMR currently causes 25 000 deaths annually and losses of
at least EUR 1.5 billion per annum in extra healthcare costs and productivity.
more
Namibia guideline for submission of applications for registration of pharmaceuticals for human use in common technical document format.
CHAPTER 15:03 | Acts 14/1969, 62/1971, 35/1974, 20/1978, 41/1978 (s. 35) 39/1979, 7/1987, 11/1988, 18/1989 (s. 27), 1/1996, 6/2000, 22/2001; R.G.N. 899/1978.
CARE International’s Personal Safety & Security Handbook has been developed to provide practical personal safety and security advice and guidance to all staff working in CARE offices and field sites throughout the world.
Each section has a detailed list of contents at the beginning and cut-ou...t tabs to allow fast access to topics. Symbols and easy referencing are used throughout the handbook to help you find what you need quickly.
more
Non-Wood Forest Products 11
Traditional medicine and its use of medicinal plants is dependent on reliable supply of plant materials. The book focuses on the interface between medicinal plant use and conservation of medicinal plants.
Medicinal plants occupied an important position in the socio-cultural, spiritual and medicinal arena of rural people of India. T
The present report is based on contribution made by members of the task force and many other experts on medicinal plants. We hope the report on implementation will promot...e sustainable and equitable development of medicinal plants sector provide "Health for All", boost exports, and will improve livelihood of the people and green the country for the present and the
generation to come.
more
Situational Analysis: 13-23 October 2014
Report prepared using the WHO/SEARO workbook tool for undertaking a situational analysis of medicines in health care delivery in low and middle income countries
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Misceláneo
Capítulo J.2
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Montserrat Pamias